Catalyst
Slingshot members are tracking this event:
Ardelyx, Inc. Expected to Release Clinical Data by Late 2017 from T3MPO-2 Trial with Tenapanor in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
Do you think this event is important to the companies below? How will it affect their stock price?
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 16, 2017
Occurred Source:
http://ir.ardelyx.com/news-releases/news-release-details/ardelyx-announces-tenapanor-reduces-pain-caused-ibs-c-through
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Irritable Bowel Syndrome, Ibs-c, Tenapanor, T3mpo-2, Nhe3 Inhibitor, Phase 3
